Navigation Links
GenomeDx Expands Collaboration with Mayo Clinic
Date:4/29/2013

SAN DIEGO, April 29, 2013 /PRNewswire/ -- GenomeDx Biosciences announced today that it has expanded an existing research agreement with the Mayo Clinic. The expanded agreement includes exclusive license to certain Mayo developed intellectual property along with exclusivity covering co-developed intellectual property.   The agreement also includes continued access to the clinical data concerning Mayo Clinic's cohort of prostate cancer samples to allow for longer-term follow up and evaluation of biomarkers. The initial collaboration entered in 2009 led to the development of Decipher™, a transformative genomic test that forecasts risk of metastasis in men with prostate cancer. In addition, GenomeDx announced that five studies evaluating the ability of Decipher to predict metastatic prostate cancer will be featured at the 2013 American Urological Association (AUA) Annual Meeting.

"Access to the Mayo Clinic's comprehensive cohort of samples from patients classified as high risk for metastatic disease and the involvement of Mayo Clinic researchers has been essential to the development of Decipher," said Doug Dolginow , M.D., Chief Executive Officer of GenomeDx. "With Mayo Clinic's large collection of patient samples that had developed metastatic disease, we could reliably identify and validate gene sequences associated with lethal prostate cancer and to create the Decipher test."

Abstracts Related to Decipher at AUA 2013

Podium presentation (May 8, 2013, 8:00-10:00 a.m. Pacific Time)

  • Validation of a genomic classifier that predicts metastatic disease progression in men with high risk pathological features post-prostatectomy, presented by R. Jeffrey Karnes , M.D., associate professor and Vice-Chair in Urology at Mayo Clinic
  • Location: San Diego Convention Center, Room 1

Poster presentations (May 8, 2013, 10:30 a.m.-12:30 p.m. Pacific Time)

  • Comparison of clinical and genomic models for prediction of rapid metastatic disease after radical prostatectomy, Abstract 2229; presented by Ashley Ross , M.D., Ph.D., assistant professor in the departments of urology, oncology and pathology and Johns Hopkins School of Medicine
  • Performance of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy, Abstract 2240; presented by Ashley Ross , M.D., Ph.D., assistant professor in the departments of urology, oncology and pathology and Johns Hopkins School of Medicine
  • Combined value of genomic biomarkers and CAPRA-S in predicting prostate cancer death in a high-risk surgical cohort, Abstract 2243; presented by Matthew Cooperberg , M.D., assistant professor of urology; epidemiology & biostatistics, University of California, San Francisco
  • Evaluation of a genomic classifier for improved risk stratification in prostate cancer patients with specific adverse pathologies after surgery, Abstract 2230; presented by Doug Dolginow , M.D., CEO GenomeDx Biosciences
  • All posters located in San Diego Convention Center, Room 11

Abstracts for all Decipher studies presented at AUA can be found by searching for the keyword "Decipher" at http://www.aua2013.org/abstracts/index2.cfm.

About GenomeDx Biosciences
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that have a real impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. The company's first test, Decipher™, is a transformative prognostic test that provides a direct measure of the true biological risk of metastatic prostate cancer independent of PSA and other risk factors. GenomeDx is based in San Diego, California and Vancouver, British Columbia. More information is available at www.genomedx.com.

Mayo Clinic has a financial interest in technology licensed to GenomeDx.


'/>"/>
SOURCE GenomeDx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millstone Medical Outsourcing Expands Medical Device Distribution Services
2. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
3. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
4. Relievant Medsystems Achieves Completion of Interim Safety Data Analysis of Intracept in SMART Pivotal Study and Expands Senior Leadership Team
5. Western Maryland Health System Expands Use of Versus RTLS to Enhance Staff Safety
6. Compass Diversified Holdings Expands Term Loan Facility by $30 Million and Lowers Interest Rate by 1.25%
7. Phonak Expands Its Quest Platform with New Product Lines
8. Everyday Health Expands Solutions For Pharmaceutical Industry Marketers
9. BioElectronics Expands European Distribution to Malta
10. SAFC Expands PharmaGrade Raw Materials Portfolio to Meet Growing Demand; Expects to Double PharmaGrade Portfolio in 2013
11. Accelovance Expands Oncology Leadership with the Addition of Ralph Boccia, MD as Oncology Medical Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research and Markets ... Report" report to their offering. ... This report analyzes the worldwide markets for ... US, Canada , Japan , ... , and Rest of World. Annual estimates and forecasts are provided ...
(Date:12/8/2016)... 2016 Bodycad announced it has been ... accuracy, reproducibility and speed for 3D constructs via ... bone orthopaedic applications. These patents are critical to ... restorations based on each patient,s distinct anatomy. ... harnesses the world,s first suite of orthopaedic CAD/CAM ...
(Date:12/8/2016)... , Dec. 8, 2016 True Health ... brings leading-edge laboratory services and management expertise to ... , allowing more doctors and patients to ... management solutions. Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... Hospital systems, under pressure to contain costs, have ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):